BioXcel Therapeutics, Inc.
BTAIQ
$0.05
$0.009.56%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -14.52% | -63.28% | -71.67% | -66.96% | -63.88% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -14.52% | -63.28% | -71.67% | -66.96% | -63.88% |
| Cost of Revenue | -83.61% | -79.16% | -92.35% | -52.42% | 55.19% |
| Gross Profit | 131.39% | 209.29% | 291.80% | -184.80% | -221.26% |
| SG&A Expenses | 2.08% | -18.35% | -40.58% | -48.04% | -59.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.87% | -2.89% | -24.10% | -33.07% | -52.32% |
| Operating Income | 10.81% | 0.69% | 22.43% | 32.03% | 52.06% |
| Income Before Tax | -39.08% | -88.04% | -17.28% | 3.92% | 52.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -39.08% | -88.04% | -17.28% | 3.92% | 52.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -39.08% | -88.04% | -17.28% | 3.92% | 52.75% |
| EBIT | 10.81% | 0.69% | 22.43% | 32.03% | 52.06% |
| EBITDA | 10.71% | 0.64% | 22.53% | 32.15% | 52.21% |
| EPS Basic | 70.21% | 57.59% | 74.15% | 71.84% | 77.72% |
| Normalized Basic EPS | 68.85% | 54.54% | 73.24% | 71.13% | 77.74% |
| EPS Diluted | 70.21% | 57.59% | 74.15% | 71.84% | 77.72% |
| Normalized Diluted EPS | 68.85% | 54.54% | 73.24% | 71.13% | 77.74% |
| Average Basic Shares Outstanding | 389.64% | 417.46% | 380.89% | 234.79% | 126.31% |
| Average Diluted Shares Outstanding | 389.64% | 417.46% | 380.89% | 234.79% | 126.31% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |